PD-1 Inhibitors Development Services
Alfa Cytology provides PD-1 blocker development services. PD-1 Inhibitors Development Services provides drug design and initial screen to find the small molecules that prevent PD-1 from binding to its ligand. We specialize in leukemia drug development to expand the use of PD-1 Inhibitors in the therapy and management of leukemia. The development of immune checkpoint blocking immunotherapies holds the promise of transforming the therapy of leukemia.
Functional Roles of PD-1 Checkpoint in Leukemia
PD-1 plays a critical role in immune regulation, and the use of PD-1 inhibitors can restore immune cell activity, enhance immune attack against tumor cells. PD-1 inhibitors can block the binding of PD-1 to PD-L1 or PD-L2, thus restoring the ability of immune cells to attack tumor cells. These drugs have been widely used in the therapy of various malignancies and have shown significant efficacy. Clinical trials related to leukemia suggest that anti-PD-1 drugs may have a potential therapeutic effect on patients.
Fig. 1. The regulation of the PD-1/PD-L1 pathway in leukemia. (Cao, H., et al., 2023)
Our bioassay services evaluate PD-1/PD-L1 blockade and small molecule binding affinity, crucial in bioassays. We offer diverse tests, including biophysical, biochemical, in vitro cellular, and in vivo tumor xenograft models, providing comprehensive assessments of small molecule inhibitors' effectiveness against PD-1.
Binding Affinity Measurement of PD-1 Inhibitors
The interaction between PD-1 can be characterized using a range of methods provided by us. The data we provide, which measures the critical parameters of the binding capacity between potential inhibitors and PD-1 proteins, is valuable for screening PD-1 inhibitors for leukemia. We offer the following methods for binding affinity measurement.
- Surface plasmon resonance (SPR)
- Microscale thermophoresis (MST)
- Biolayer interferometry
(BLI) - Differential scanning fluorometry (DSF)
- Isothermal titration calorimetry (ITC)
- Fluorescence polarization immunoassay (FPIA)
Assays Services for PD-1 Inhibitors
Luciferase Reporter Assay
We provide a tool for PD-1 inhibitors screening and characterization. To screen for PD-1 inhibitors, we use reporter gene-based PD-1 cells. This enables screening of the most promising hits from a large library of compounds and provides results on PD-1 signaling (agonistic vs antagonistic).
T cell-based assay
Our T cell-based detection services are provided to validate the biological functionality of PD-1 inhibitors and assess the blocking capacity and biological functionality of PD-1 inhibitors. The T cell-based detection includes effector cells expressing PD-1, cells presenting PD-L1, and activation signals for effector cells.
Enzyme-linked Immunosorbent Assay
Our ELISA assay detects the presence of proteins by utilizing antibodies specific to the target protein. We employ PD-1 paired ELISA to screen small molecules that exhibit blocking effects on PD-1 interactions. Additionally, we offer a variety of PD-1 assay kits for screening inhibitors of PD-1 interactions.
In-Vivo Cancer Therapeutic Testing
We offer comprehensive services for preclinical testing of anticancer therapies in leukemia xenograft models or xenografts derived from cell lines to assess the effectiveness of developed PD-1 inhibitors. We provide a variety of leukemia models and services, fully customizable to meet your research needs.
Development Process of PD-1 Inhibitors
We provide a range of assays, including binding affinity assay, blockage ability assay, cell-based functional assays, and xenograft models, to identify novel PD-1 inhibitors for our clients. These comprehensive assays offer the potential to discover new drugs for the therapy of leukemia.
Binding Affinity Assay
Blockage Ability Assay
Cell-based Founctional Assay
Xenograft Model Assay
SPR MST DSF
FPIA NMR
ELISA
Luciferase Assay
T cell-based assay
HL-60 K-562
MOLM13 MOLT-4
Advantages of Our Services
- Obtain prompt answers to inquiries or receive efficient guidance for your projects.
- Screening of PD-1 inhibitors using standard experimental procedures.
- Compound libraries consisting of small molecules with proven biological and pharmacological activity.
Alfa Cytology specializes in drug development for leukemia, aiming to harness the potential of PD-1 inhibitors in leukemia therapy. Our customized PD-1 inhibitor development services cover the entire project's research and development phases, allowing us to flexibly meet your specific research needs. Contact us for more information or to have your questions answered.
References
- Cao, H.; et al. Progress of research on PD-1/PD-L1 in leukemia. Frontiers in Immunology. 2023, 14: 1265299.
- Liu, C.; et al. Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: A review. Cancer Cell International. 2021, 21(1): 1-17.